The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.
The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.
CGI will provide target identification and biomarker discovery services for three cancer drugs that BeiGene is currently developing.
The firm saw a 204 percent increase in clinical services test volume year over year driven by increased offerings in several testing services.
The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.
The partners said they will also combine their respective expertise to offer pharmaceutical companies help in developing companion diagnostics for oncology.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
The company said it plans to use the proceeds of the offering for general corporate purposes.
The firm said its Focus::Myeloid NGS-based panel for myeloid malignancies provides information for diagnosis, prognosis, treatment, and risk stratification of patients.
In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.
Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.
Researchers are using gene editing to develop more robust livestock and crops, AFP reports.
Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.